Table 3.
Main characteristics of 24 patients at onset of t(5;14)(q31;q32) B-ALL -our patients (n = 8) and patients from literature (n = 16).
| Clinical presentation* | |
|---|---|
| Age (years) (median) [range] | 14.3 [4–60] |
| Sex ratio (male/female) | 20/4 (5) |
| Organomegaly | 10/19 (53%) |
| Lung involvement | 10/20 (50%) |
| Thrombo-embolic event | 5/19 (26%) |
| Cardiac involvement | 9/19 (47%) |
| Neurologic involvement | 5/19 (26%) |
| Skin involvement | 5/19 (26%) |
| Peripheral blood (median) [range] | |
| White blood cells (×109/L) | 72 [15.9–148.3] |
| Eosinophils (×109/L) | 31.7 [6–111] |
| Basophils (×109/L) | 0.8 [0–7] |
| Neutrophils (×109/L) | 9.7 [1.4–27.4] |
| Lymphocytes (×109/L) | 5.8 [2.7–13.1] |
| Monocytes (×109/L) | 0.9 [0.45–2.8] |
| Hemoglobin (g/dL) | 12 [7–13.7] |
| Platelet (×109/L) | 171 [60–532] |
| Blasts (×109/L) | 0 [0–36.6] |
| Bone marrow morphology (median) [range] | |
| Blasts (%) | 42 [5–80]** |
| Eosinophils (%) | 24 [7–53] |
| Basophils (%) | 1 [0–1.5] |
| Immunophenotypic features* | |
| Immunophenotype (EGIL classification) | 1/12 BI 7/12 BII 4/12 BIII |
| Myeloid markers (CD13+, CD33+) | 4/13 (31%) |
| Cytogenetic features (median) [range] | |
| Abnormal metaphases (%) | 20 [3–100] |
| Additional cytogenetic abnormalities (%) | 9/24 (37.5%) |
| Response to treatment* | |
| Complete remission after induction therapy | 9/14 |
| Relapse | 9/14 |
*
The variable number of evaluable patients in the literature according to the different items explains a denominator <24.
**
The presence of the t(5;14)(q31;q32) allows diagnosis of cases with <20% blast cells according to WHO classification.